Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Toniva Boone"'
1
Akademický článek
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Autor: Kartik Anand, Tejal Patel, Polly Niravath, Angel Rodriguez, Jorge Darcourt, Anna Belcheva, Toniva Boone, Joe Ensor, Jenny Chang
Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Triple-negative breast cancer (TNBC) patients who do not achieve pathologic complete response post neoadjuvant chemotherapy have a poor prognosis. Alteration in PI3K/mTOR plus DNA repair pathways are some of the major mechanisms of chemother
Externí odkaz: https://doaj.org/article/d34983028cb9441c92231a1bc62f5312
Zobrazit plný text záznamu
2
Akademický článek
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Autor: Tejal A. Patel, Joe E. Ensor, Sarah L. Creamer, Toniva Boone, Angel A. Rodriguez, Poly A. Niravath, Jorge G. Darcourt, Jane L. Meisel, Xiaoxian Li, Jing Zhao, John G. Kuhn, Roberto R. Rosato, Wei Qian, Anna Belcheva, Mary R. Schwartz, Virginia G. Kaklamani, Jenny C. Chang
Publikováno v: Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background Neoadjuvant dual human epidermal growth factor receptor (HER2) blockade with trastuzumab and pertuzumab plus paclitaxel leads to an overall pathologic complete response (pCR) rate of 46%. Dual HER2 blockade with ado-trastuzumab em
Externí odkaz: https://doaj.org/article/4491401233a240d9afeec8c1bf909d3d
Zobrazit plný text záznamu
3
ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer
Autor: Emre Koca, Virginia G. Kaklamani, Adam L. Cohen, Sindhu Nair, Jorge Darcourt, Asha Murthy, Anna Belcheva, Helen Wong, Toniva Boone, Joe Ensor, Pej Hemati, Polly A. Niravath, Wei Qian, Priya V. Ramshesh, Jing Zhao, Jenny C. Chang, Tejal Patel, Xiaoxian Li
Publikováno v: Breast Cancer Research and Treatment. 188:433-439
Neoadjuvant endocrine therapy is often utilized to downstage Estrogen Receptor-positive (ER+) breast cancer prior to surgery. However, this approach is sometimes met with endocrine resistance mechanisms within the tumor. This trial examines the safet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07d5dd2ca376ce58ced66f0e08ef0142
https://doi.org/10.1007/s10549-021-06214-7
Zobrazit plný text záznamu
4
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Autor: Tejal Patel, Toniva Boone, Jenny C. Chang, Angel Rodriguez, Polly A. Niravath, Kartik Anand, Jorge Darcourt, Joe Ensor, Anna Belcheva
Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Scientific Reports
Triple-negative breast cancer (TNBC) patients who do not achieve pathologic complete response post neoadjuvant chemotherapy have a poor prognosis. Alteration in PI3K/mTOR plus DNA repair pathways are some of the major mechanisms of chemotherapy resis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6b89704a9b4576acf99fb1a8645e941
https://doi.org/10.1038/s41598-020-80081-y
Zobrazit plný text záznamu
5
A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer
Autor: Stephen T. C. Wong, Kartik Anand, Angel Rodriguez, Tejal Patel, Jenny C. Chang, Polly A. Niravath, Toniva Boone, Joe Ensor
Publikováno v: Clin Breast Cancer
Chemotherapy eliminates most cancer cells except cancer stem cells. Chloroquine is a potential agent to target cancer stem cells. In this phase II trial for patients with breast cancer who were refractory to anthracycline-based chemotherapy, we combi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::928a8fd34d6202d02cecd2a82a1a483c
https://pubmed.ncbi.nlm.nih.gov/34159901
Zobrazit plný text záznamu
6
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Autor: Sarah L. Creamer, Mary R. Schwartz, Xiaoxian Li, Wei Qian, Polly A. Niravath, Roberto R. Rosato, Tejal Patel, Virginia G. Kaklamani, Jane L. Meisel, Angel Rodriguez, Jorge Darcourt, Jing Zhao, Jenny C. Chang, Anna Belcheva, Toniva Boone, Joe Ensor, John G. Kuhn
Publikováno v: Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Breast Cancer Research : BCR
Background Neoadjuvant dual human epidermal growth factor receptor (HER2) blockade with trastuzumab and pertuzumab plus paclitaxel leads to an overall pathologic complete response (pCR) rate of 46%. Dual HER2 blockade with ado-trastuzumab emtansine (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::274060c919472668a43fbb6066240249
https://doi.org/10.1186/s13058-019-1186-0
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje